Shares of Adaptive Biotechnologies (ADPT) have been strong performers lately, with the stock up 14.1% over the past month. The stock hit a new 52-week high of $24.34 in the previous session. Adaptive Biotechnologies has gained 48.9% since the start of the year compared to the 1.2% move for the Zacks Medical sector and the 3.3% return for the Zacks Medical - Biomedical and Genetics industry.
What's Driving the Outperformance?
The stock has an impressive record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on July 29, 2026, Adaptive Biotechnologies reported EPS of -$0.1 versus consensus estimate of -$0.13.
For the current fiscal year, Adaptive Biotechnologies is expected to post earnings of -$0.46 per share on $287.33 in revenues. This represents a 23.33% change in EPS on a 3.74% change in revenues. For the next fiscal year, the company is expected to earn -$0.21 per share on $351.82 in revenues. This represents a year-over-year change of 54.35% and 22.44%, respectively.
Valuation Metrics
While Adaptive Biotechnologies has moved to its 52-week high in the recent past, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Adaptive Biotechnologies has a Value Score of D. The stock's Growth and Momentum Scores are A and B, respectively, giving the company a VGM Score of B.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this is even more important than the company's VGM Score. Fortunately, Adaptive Biotechnologies currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Adaptive Biotechnologies meets the list of requirements. Thus, it seems as though Adaptive Biotechnologies shares could have potential in the weeks and months to come.
How Does ADPT Stack Up to the Competition?
Shares of ADPT have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Halozyme Therapeutics, Inc. (HALO). HALO has a Zacks Rank of #2 (Buy) and a Value Score of B, a Growth Score of A, and a Momentum Score of F.
Earnings were strong last quarter. Halozyme Therapeutics, Inc. beat our consensus estimate by 3.90%, and for the current fiscal year, HALO is expected to post earnings of $7.96 per share on revenue of $1.77 billion.
Shares of Halozyme Therapeutics, Inc. have gained 4.9% over the past month, and currently trade at a forward P/E of 10.47X and a P/CF of 17.46X.
The Medical - Biomedical and Genetics industry is in the top 35% of all the industries we have in our universe, so it looks like there are some nice tailwinds for ADPT and HALO, even beyond their own solid fundamental situation.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.